​

Funding Round

Series B - Cyteir Therapeutics

Series B - Cyteir Therapeutics

Investment Firm

Overview

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

Announced Date

Mar 08, 2018

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Venrock

Venrock

Venrock is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorDroia Ventures
Participant InvestorCelgene
Participant InvestorLightstone Ventures
Participant InvestorVenrock
Participant InvestorOUP (Osage University Partners)

Round Details and Background

Cyteir Therapeutics raised $29000000 on 2018-03-08 in Series B

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 15, 2019
Series B - Cyteir Therapeutics
6-40.2M
Feb 11, 2021
Series C - Cyteir Therapeutics
12-80.0M
Jun 29, 2016
Grant - Cyteir Therapeutics
1-2.0M
Nov 05, 2015
Series A - Cyteir Therapeutics
1-5.5M

Recent Activity

There is no recent news or activity for this profile.